A Phase IV Study in Drug-Naive Patients With T2DM in China
Status:
Terminated
Trial end date:
2019-05-24
Target enrollment:
Participant gender:
Summary
This is a 24-week, multicenter, randomized, open-label, parallel-group, active controlled
Phase IV study to assess the efficacy and safety of Dapagliflozin as monotherapy compared
with Acarbose in patients with T2DM who were inadequately controlled with diet and exercise.
The study is designed to evaluate the efficacy and safety of dapagliflozin monotherapy
compared with acarbose monotherapy in patients with T2DM inadequately controlled with diet
and exercise.